Sign in
4

Changes in Ownership

Acrivon Therapeutics, Inc. Filed Acc 0001209191-22-057395

President and CEO acquired 1,524,947 shares (grant or award)

From the SEC's structured data for this filing

Trades in this filing

Blume-Jensen Peter · President and CEO

Table I: Non-derivative

4 lines
Date Transaction Shares Owned after D/I
2022-11-14 Grant or award : show line 1 in the form +934,731 1,806,588 D
2022-11-14 Grant or award : show line 2 in the form +503,419 2,310,007 D
2022-11-14 Grant or award : show line 3 in the form +60,090 2,370,097 D
2022-11-14 Grant or award : show line 4 in the form +26,707 320,705 I

Table II: Derivative

2 lines
Date Transaction Shares Owned after D/I
2022-11-14 Grant or award : show line 5 in the form Stock Option (Right to Buy) +180,269 180,269 D
2022-11-14 Grant or award : show line 6 in the form Stock Option (Right to Buy) +80,120 80,120 I
Loading xslF345X03/doc4.xml…